LabTwin Named a Finalist in 2019 Fierce Innovation Awards
The company was recognized in the Technology Innovation category, which acknowledges products and services that use technology solutions to serve the industry and promote innovations.
LabTwin, a voice- and artificial-intelligence-powered digital lab assistant, was named a finalist in Questex’s Fierce Innovation Awards-LifeSciences Edition in the Technology Innovation category, according to a Dec. 12, 2019 announcement. The Technology Innovation category recognizes products and services that use technology solutions to serve the industry and promote innovations, according to Questex’s 2019 innovation report.
The device, which reduces error rates and improves research efficiency with its voice-powered technology, was selected by a panel of judges from biotech and pharma companies, including Astellas, PPD Corporate Development & Strategy, Signant Health, Medidata Solutions, Accenture’s Global Applied Life Sciences Solutions Practice, Angelica Therapeutics, National Institute for Health Research’s Clinical Research Network, Biotech Research Group, Ostuaka Pharmaceuticals, AstraZeneca, and BrightInsight, a Flex Company.
“We are honored to be recognized as a finalist among other innovative tech companies for the life sciences community,” said Magdalena Paluch, co-founder and CEO of LabTwin, in a company press release. “LabTwin’s voice-powered assistant is used by hundreds of scientists in leading biopharma companies and academic institutions around the world, and we’re pleased to see that our product is making a difference in their research and discoveries.”
Later in December 2019, Questex announced that Cognoa, a pediatric behavioral health company in Palo Alto, CA, took home first place in the Technology Innovation category.
Clinical Supply Planning in Europe - Balancing Cost, Flexibility and Time
December 19th 2024The packaging and distribution of clinical supplies is a fundamental piece to the overall success of a clinical trial, and advance preparation can help establish a more efficient supply chain. Selecting the best geographical location for those activities, however, depends on the clinical trial protocol, business decisions, and even the investigational medicinal product (IMP) being studied.
